FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
Mining equities like Argo Blockchain and Hive Digital are posting massive gains, outperforming Bitcoin as investors seek high-beta crypto exposure.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
New trade measure seen as a significant tailwind for domestic transport and logistics companies, boosting sector stocks.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.